Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
Want to see ALLR full AI Analyst Report?
Top Page
Allarity Therapeutics
(NASDAQ:ALLR)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.50
▲(31.58% Upside)
Action:Reiterated
Date:05/22/26
The score is held down primarily by weak financial performance (large losses and significant cash burn with ongoing funding risk). Technical momentum is currently supportive and offsets some risk, but valuation is not supportive due to unprofitability, and recent financing terms add caution despite positive clinical/investor visibility updates.
Positive Factors
Proprietary DRP biomarker platform
Allarity’s proprietary Drug-Response Predictor (DRP) is a durable competitive asset: biomarker-driven patient selection can raise clinical success rates, improve trial efficiency, and increase partner and payer interest. This structural capability supports differentiated development and commercialization paths over months.
Negative Factors
High cash burn and negative operating cash flow
Sustained negative operating and free cash flow at roughly -$16.6M to -$17.0M TTM signals heavy cash consumption relative to current resources. This structural burn requires recurring external funding or major spending cuts, pressuring continuity of R&D programs and increasing dilution risk over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary DRP biomarker platform
Allarity’s proprietary Drug-Response Predictor (DRP) is a durable competitive asset: biomarker-driven patient selection can raise clinical success rates, improve trial efficiency, and increase partner and payer interest. This structural capability supports differentiated development and commercialization paths over months.
Read all positive factors
Allarity Therapeutics (ALLR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.75M
Dividend YieldN/A
Average Volume (3M)146.33K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue GrowthN/A
EPS Growth94.17%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.72
Shares Outstanding15,910,724
10 Day Avg. Volume114,973
30 Day Avg. Volume146,334
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.58
Price to Sales (P/S)48.53
P/FCF Ratio-1.05
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue80.51
Enterprise Value/Gross Profit74.87
Enterprise Value/Ebitda-2.54
Forecast
1Y Price Target
$9.75Price Target Upside755.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)N/A
Allarity Therapeutics Business Overview & Revenue Model
Company Description
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which ...
How the Company Makes Money
null...
Allarity Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
16
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 320.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 320.00K | 0.00 | -37.00K | -120.00K | -106.00K |
| EBITDA | -11.05M | -24.23M | -11.28M | -17.30M | -25.77M |
| Net Income | -11.23M | -24.52M | -11.90M | -16.06M | -26.65M |
Balance Sheet | |||||
| Total Assets | 18.26M | 22.65M | 11.86M | 14.54M | 49.63M |
| Cash, Cash Equivalents and Short-Term Investments | 14.69M | 19.53M | 166.00K | 2.03M | 19.91M |
| Total Debt | 1.40M | 1.35M | 1.30M | 3.73M | 1.09M |
| Total Liabilities | 8.43M | 10.84M | 14.61M | 12.65M | 30.85M |
| Stockholders Equity | 9.83M | 11.81M | -2.75M | 1.89M | 18.78M |
Cash Flow | |||||
| Free Cash Flow | -14.83M | -17.65M | -12.74M | -16.84M | -15.05M |
| Operating Cash Flow | -14.82M | -17.35M | -12.74M | -16.82M | -15.05M |
| Investing Cash Flow | -8.00K | -298.00K | 0.00 | 791.00K | 1.00M |
| Financing Cash Flow | 10.65M | 36.79M | 10.99M | -1.31M | 33.82M |
Allarity Therapeutics Technical Analysis
Neutral
1.14
Price Trends
1.45
Positive
1.25
Positive
1.30
Positive
Market Momentum
0.01
Positive
46.88
Neutral
21.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLR, the sentiment is Neutral. The current price of 1.14 is below the 20-day moving average (MA) of 1.60, below the 50-day MA of 1.45, and below the 200-day MA of 1.30, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 46.88 is Neutral, neither overbought nor oversold. The STOCH value of 21.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALLR.
Allarity Therapeutics Risk Analysis
Allarity Therapeutics disclosed 79 risk factors in its most recent earnings report. Allarity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allarity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $22.75M | -2.10 | -112.05% | ― | ― | 94.17% | |
47 Neutral | $24.76M | -0.87 | -119.92% | ― | -45.35% | 58.32% | |
45 Neutral | $32.42M | -1.90 | -101.90% | ― | -83.00% | 19.02% | |
44 Neutral | $16.41M | -3.80 | 354.21% | ― | -36.95% | 80.84% |
* Healthcare Sector Average
ALLR
Allarity Therapeutics
1.48
0.65
78.31%
LSTA
Lisata Therapeutics
3.45
0.94
37.45%
CRIS
Curis
0.42
-2.06
-83.20%
LGVN
Longeveron
0.79
-0.50
-38.76%
Allarity Therapeutics Corporate Events
Executive/Board Changes
Allarity Therapeutics Updates CEO Management and Compensation Agreement
Neutral
Jun 2, 2026
Effective June 1, 2026, Allarity Therapeutics entered into an Amended and Restated Management Services Agreement with Ljungaskog Consulting AB, which replaces the original June 1, 2024 pact governing CEO Thomas H. Jensen’s services. The revi...
Business Operations and StrategyProduct-Related Announcements
Allarity Highlights Stenoparib Progress in New Investor Presentation
Positive
May 8, 2026
Allarity Therapeutics said it will begin using a new corporate presentation with investors, analysts and other audiences starting May 11, 2026, outlining its DRP companion diagnostics platform and the clinical progress of its lead asset stenoparib...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.